SynthesisMedical oncology (Northwood, London, England)2010
Association between EGF promoter polymorphisms and cancer risk: a meta-analysis.
Synthesis in Medical oncology (Northwood, London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 5 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Cumulative evidence for association between genetic polymorphisms and esophageal cancer susceptibility: A review with evidence from meta-analysis and genome-wide association studies.Cancer medicine · 2019Pooled it
- Association between EGF +61 A>G polymorphism and gastric cancer risk: A meta-analysis.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2015Pooled it
- Quantitative assessment of the association between +61A>G polymorphism of epidermal growth factor gene and susceptibility to glioma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Epidermal growth factor 61A>G polymorphism is associated with risk of hepatocellular carcinoma: a meta-analysis.Genetic testing and molecular biomarkers · 2012Pooled it
- Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis.PloS one · 2012Pooled it
- A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.Gastroenterology · 2011Trial
- Genetic Polymorphism of Epidermal Growth Factor Gene as a Predictor of Hepatocellular Carcinoma in Hepatitis C Cirrhotic Patients.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Association of the epidermal growth factor gene +61A>G polymorphism with hepatocellular carcinoma in an Iranian population.Gastroenterology and hepatology from bed to bench · 2017Article
- Correlation between the EGF gene intronic polymorphism, rs2298979, and colorectal cancer.Oncology letters · 2013Article
- Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk.Carcinogenesis · 2013Article
- The effect of 5'untranslated region polymorphism in EGF gene, rs4444903, on colorectal cancer.Gastroenterology and hepatology from bed to bench · 2013Article
- Analysis of EGF+61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy.Journal of cancer research and clinical oncology · 2012Article
- A functional +61G/A polymorphism in epidermal growth factor is associated with glioma risk among Asians.PloS one · 2012Article
- Association between EGF +61A/G polymorphism and gastric cancer in Caucasians.World journal of gastroenterology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EGF promoter polymorphisms are observed to modulate EGF levels and thought to have effect on susceptibility to various carcinomas but the results are inconsistent. In this meta-analysis, we assessed published studies of the association between three EGF polymorphisms and cancer risk from 21 studies with 14,609 subjects for EGF G61A, from two studies with 2,535 subjects for G-1380A and A-1744G, respectively. For EGF G61A, the contrast of homozygote (OR=0.80, 95% CI=0.65-0.98), allele (OR=0.90, 95% CI=0.81-0.99) and dominant model (OR=0.86, 95% CI=0.74-0.99) produced significant association among 21 studies with relatively large heterogeneity (Pheterogeneity<0.001). Through the stratified analysis, heterogeneity decreased significantly. In the stratified analysis by racial descent, the significant risks were found among Asians for homozygote contrast (OR=0.83, 95% CI=0.69-0.99, Pheterogeneity=0.506) and Americans for the contrast of homozygote (OR=0.50, 95% CI=0.30-0.84, Pheterogeneity=0.051), allele (OR=0.70, 95% CI=0.51-0.96, Pheterogeneity=0.008) and dominant model (OR=0.57, 95% CI=0.42-0.77, Pheterogeneity=0.28). No significant associations were found in all Caucasians genetic models. In the subgroup analyses by cancer types, for gastric cancer and esophageal cancer significant associations were found in all genetic models without heterogeneity. Significant risk was also found in the contrast of homozygote (OR=0.41, 95% CI=0.20-0.81, Pheterogeneity=0.184) and recessive model (OR=0.53, 95% CI=0.33-0.85, Pheterogeneity=0.384) for hepatoma and recessive model (OR=0.72, 95% CI=0.53-0.99, Pheterogeneity=0.474) for glioma. For EGF G-1380A and A-1744G, no significant associations were found in all genetic models. This meta-analysis suggests that the EGF G61A polymorphism most likely contributes to decreased susceptibility to cancers among Asians and Americans, and A allele may be a protective factor for gastric cancer, esophageal cancer, hepatoma and glioma. Both EGF G-1380A and A-1744G is marginally associated with cancer susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.